ArticleFrontiers in veterinary science2025
A high content (30%) stable doxycycline hyclate drinking-water solution for broilers: preparation, stability, and bioequivalence.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Doxycycline is a semi-synthetic tetracycline antibiotic with broad-spectrum antimicrobial activity. Under intensive animal husbandry, commercially available doxycycline drinking-water formulations often show several drawbacks in solubility, stability and homogeneous distribution under farm conditions. To overcome these limitations, we developed a high content (30%, w/v), pilot-scale, stable doxycycline hyclate solution (DOX·HCl solution) specifically designed for drinking-water administration. A comprehensive quality assessment of this system was performed, followed by a bioequivalence evaluation of its application in broilers. Method: Prescription selection through high-temperature testing was combined with preparation process study via single-factor screening to prepare DOX·HCl solution. Quality assessment included assay of DOX, the dilutability and dilution stability testing, evaluation of mixed performance, and the stability studies. Bioequivalence study was conducted in a randomized, parallel, and blinded design to compare the DOX·HCl solution with two commercially available doxycycline hyclate drinking-water products. Results: Three pilot-scale batches of the 30% DOX·HCl solution (mean content 100.14 ± 0.37%) were successfully manufactured under controlled conditions of 400 rpm stirring and 60 °C. These pilot samples remained stable in appearance and content when diluted with water for up to 24 h. Affecting factor testing, accelerated testing and long-term testing all showed good stability, with an expiration date exceeding 24 months. In broilers, the DOX·HCl solution achieved a T Conclusion: The 30% DOX·HCl solution represents a high-content, industrially scalable drinking-water concentrate that combines long-term physicochemical stability with bioequivalence to existing products. This formulation offers a more convenient and highly efficient reliable option that could be a potential alternative to commercial products for mixed drinking-water medication of livestock and poultry, particularly under high-density, centralized management conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.